Stock listing
NASDAQ:ODTX Odyssey Therapeutics, Inc. Stock
Home listing (NASDAQ) of Odyssey Therapeutics, Inc.
Follow Odyssey Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ODTX
$16.96 USD -2.02 (-10.6%)
Close on Nov 20, 2026
- Day range
- $16.46 – $18.08 USDNov 20, 2026
- Volume
- 677,842 sharesNov 20, 2026
- Market cap
- $815.2M USDAt the close on Nov 20, 2026 · price × 48.07M shares outstanding
- Traded on an average day
- $6.86M USDMedian day 255,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ODTX · Home | $16.96 USD | -2.02 (-10.6%) | 677,842 | $17.65 | $18.08 | $16.46 | $18.98 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ODTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $16.96 | -2.02 | -10.6% | $17.65 | $18.08 | $16.46 | 677,842 | |
| $18.98 | -0.39 | -2.0% | $19.26 | $19.98 | $18.82 | 369,096 | |
| $19.37 | +0.01 | +0.1% | $19.38 | $19.71 | $18.91 | 301,614 | |
| $19.36 | +0.22 | +1.1% | $18.87 | $19.67 | $18.57 | 340,246 | |
| $19.14 | -0.96 | -4.8% | $19.76 | $19.76 | $18.46 | 322,921 | |
| $20.10 | -0.89 | -4.2% | $20.81 | $20.81 | $19.08 | 321,972 | |
| $20.99 | +0.99 | +4.9% | $19.98 | $21.21 | $19.22 | 245,072 | |
| $20.00 | +0.85 | +4.4% | $18.98 | $20.86 | $18.71 | 395,007 | |
| $19.15 | -0.08 | -0.4% | $19.53 | $19.72 | $18.38 | 621,338 | |
| $19.23 | +0.35 | +1.9% | $18.99 | $19.70 | $18.01 | 577,256 | |
| $18.88 | -0.62 | -3.2% | $19.50 | $19.81 | $18.37 | 433,829 | |
| $19.50 | -2.07 | -9.6% | $21.89 | $22.36 | $19.00 | 675,498 | |
| $21.57 | +2.04 | +10.4% | $19.72 | $21.77 | $19.70 | 412,225 | |
| $19.53 | -0.01 | -0.1% | $19.83 | $20.66 | $18.72 | 258,944 | |
| $19.54 | -0.29 | -1.5% | $19.77 | $20.20 | $19.12 | 166,398 | |
| $19.83 | +0.29 | +1.5% | $19.70 | $20.62 | $18.70 | 212,829 | |
| $19.54 | +0.04 | +0.2% | $19.33 | $20.07 | $19.19 | 210,309 | |
| $19.50 | +0.20 | +1.0% | $19.37 | $19.98 | $18.74 | 241,163 | |
| $19.30 | -0.30 | -1.5% | $19.60 | $19.68 | $18.62 | 139,918 | |
| $19.60 | +0.52 | +2.7% | $19.02 | $20.07 | $18.37 | 209,300 | |
| $19.08 | +0.08 | +0.4% | $18.84 | $19.32 | $18.52 | 141,800 | |
| $19.00 | +0.01 | +0.1% | $18.93 | $19.79 | $18.00 | 255,300 | |
| $18.99 | +0.89 | +4.9% | $17.79 | $19.73 | $16.93 | 317,300 | |
| $18.10 | +0.93 | +5.4% | $16.94 | $18.50 | $16.94 | 300,400 | |
| $17.17 | -0.40 | -2.3% | $17.45 | $17.50 | $16.90 | 219,400 | |
| $17.57 | +0.97 | +5.8% | $16.62 | $17.75 | $16.36 | 159,000 | |
| $16.60 | -0.64 | -3.7% | $16.87 | $17.35 | $16.51 | 245,600 | |
| $17.24 | -1.02 | -5.6% | $18.15 | $18.40 | $17.18 | 258,800 | |
| $18.26 | -0.74 | -3.9% | $18.88 | $19.15 | $18.16 | 282,700 | |
| $19.00 | +0.88 | +4.9% | $18.72 | $19.65 | $18.49 | 325,600 | |
| $18.12 | +0.04 | +0.2% | $17.83 | $18.38 | $17.13 | 414,200 | |
| $18.08 | -0.05 | -0.3% | $18.01 | $18.84 | $17.83 | 264,100 | |
| $18.13 | -2.71 | -13.0% | $20.84 | $20.84 | $18.06 | 340,700 | |
| $20.84 | +0.11 | +0.5% | $20.52 | $20.96 | $19.73 | 171,800 | |
| $20.73 | +0.31 | +1.5% | $20.67 | $21.60 | $20.05 | 192,500 | |
| $20.42 | -1.80 | -8.1% | $21.98 | $22.36 | $20.33 | 308,400 | |
| $22.22 | -0.22 | -1.0% | $22.48 | $23.50 | $21.70 | 334,200 | |
| $22.44 | +0.97 | +4.5% | $21.47 | $22.76 | $21.21 | 201,700 | |
| $21.47 | +0.96 | +4.7% | $20.02 | $21.65 | $19.72 | 213,100 | |
| $20.51 | +0.58 | +2.9% | $19.90 | $20.88 | $19.41 | 237,800 | |
| $19.93 | -0.83 | -4.0% | $20.77 | $21.09 | $18.77 | 396,000 | |
| $20.76 | -2.58 | -11.1% | $22.99 | $23.03 | $20.53 | 255,200 | |
| $23.34 | +0.28 | +1.2% | $23.36 | $24.33 | $22.70 | 555,200 | |
| $23.06 | -1.32 | -5.4% | $24.51 | $25.22 | $23.05 | 245,700 | |
| $24.38 | +1.16 | +5.0% | $23.35 | $25.15 | $22.88 | 2,604,300 | |
| $23.22 | +0.10 | +0.4% | $23.46 | $25.81 | $22.94 | 524,200 | |
| $23.12 | +1.13 | +5.1% | $22.18 | $23.40 | $21.82 | 591,200 | |
| $21.99 | -2.27 | -9.4% | $24.31 | $24.84 | $21.72 | 276,700 | |
| $24.26 | -0.37 | -1.5% | $24.69 | $25.29 | $23.37 | 219,000 | |
| $24.63 | +0.99 | +4.2% | $23.94 | $25.14 | $23.64 | 198,400 | |
| $23.64 | -0.87 | -3.5% | $24.09 | $25.38 | $23.50 | 192,700 | |
| $24.51 | -2.46 | -9.1% | $26.97 | $28.26 | $24.24 | 217,400 | |
| $26.97 | -1.79 | -6.2% | $28.30 | $28.87 | $26.89 | 174,700 | |
| $28.76 | +2.36 | +8.9% | $26.24 | $29.05 | $25.71 | 269,000 | |
| $26.40 | -0.22 | -0.8% | $26.88 | $27.27 | $25.62 | 189,600 | |
| $26.62 | +2.12 | +8.7% | $24.80 | $26.80 | $24.80 | 171,400 | |
| $24.50 | -0.02 | -0.1% | $24.21 | $25.23 | $24.06 | 172,800 | |
| $24.52 | +0.16 | +0.7% | $24.33 | $24.80 | $22.89 | 170,400 | |
| $24.36 | -1.62 | -6.2% | $26.05 | $26.52 | $24.25 | 117,300 | |
| $25.98 | +0.36 | +1.4% | $25.82 | $26.40 | $25.48 | 141,400 | |
| $25.62 | -0.61 | -2.3% | $26.50 | $27.33 | $24.87 | 235,700 | |
| $26.23 | +1.08 | +4.3% | $25.12 | $27.32 | $25.12 | 163,722 | |
| $25.15 | -1.24 | -4.7% | $26.39 | $28.00 | $25.05 | 257,413 | |
| $26.39 | +1.72 | +7.0% | $24.91 | $26.49 | $24.55 | 181,300 | |
| $24.67 | +0.42 | +1.7% | $24.40 | $24.77 | $23.07 | 121,600 |
- Ticker
- NASDAQ:ODTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
Latest deck · Oct 20, 2026
UEG Week 2026 Investor Webcast
Conference · 47 slides
Latest news
Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
Nov 10, 2026
Closed $20.00 (+4.4%) on Nov 10, 2026
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 4, 2026
Closed $19.50 (-9.6%) on Nov 4, 2026
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
Oct 20, 2026
Closed $18.99 (+4.9%) on Oct 20, 2026
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
Oct 12, 2026
Closed $18.26 (-3.9%) on Oct 12, 2026
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
Oct 6, 2026
Closed $18.13 (-13.0%) on Oct 6, 2026
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
Sep 16, 2026
Closed $23.12 (+5.1%) on Sep 16, 2026
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
Aug 26, 2026
Closed $25.62 (-2.3%) on Aug 26, 2026
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 4, 2026
Closed $19.96 (+10.1%) on Aug 4, 2026
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jun 17, 2026
Closed $19.07 (+3.2%) on Jun 18, 2026
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
May 7, 2026
Closed $16.42 (-8.8%) on May 8, 2026
Odyssey Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 11 in all · newest Nov 10, 2026 · oldest 2026
- Decks
- 4 decks · latest Oct 20, 2026
Where Odyssey Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ODTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ODTX | BOATS | United States | USD |
Valuation
Price/book 2.2× against a median of 3.7×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $512.7M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.11
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. · NASDAQ:ODTX | US$815.2M | US$512.7M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | 1.11 |
| Latigo Biotherapeutics, Inc. · NASDAQ:LTGO | US$861.9M | US$460.7M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Pharming Group NV · EURONEXT:PHARM | US$840.2M | US$766.4M | 34.4× | 2.0× | 19.8× | 2.9× | 6.3% | 0.4× | n/a |
| Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS | US$815.7M | US$613.4M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 1.64 |
| NATURECELL Co., Ltd. · KRX:007390 | US$798.8M | US$783.0M | n/a | 51.4× | n/a | 17.1× | −13.2% | 0.0× | n/a |
| Arbutus Biopharma Corporation · NASDAQ:ABUS | US$796.4M | US$458.9M | 3.6× | 2.5× | 3.1× | 9.3× | 121.2% | 0.0× | 1.10 |
| Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595 | US$787.5M | US$518.8M | n/a | 26.5× | n/a | 3.3× | n/a | 0.0× | n/a |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335 | US$778.7M | US$599.6M | n/a | n/a | n/a | 5.5× | n/a | 0.0× | n/a |
| Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD | US$778.1M | US$702.9M | 5.2× | 1.8× | n/a | n/a | 37.4% | n/a | 1.16 |
| Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX | US$772.7M | US$695.6M | n/a | 2.4× | n/a | n/a | −72.4% | n/a | 0.64 |
| MeiraGTx Holdings plc · NASDAQ:MGTX | US$766.4M | US$715.6M | 9.8× | 1.8× | 3.7× | 3.6× | 19.5% | 0.6× | 1.57 |
| Median of the others | US$791.9M | US$654.5M | 7.5× | 2.4× | 3.7× | 3.7× | 12.9% | 0.0× | 1.16 |
Forecasts
Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 34.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.60 · 2 analysts
Team and board
| Officer | Role |
|---|---|
| Gary D. Glick | Founder, President & CEO |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | −9.6% |
| Q2 2026 | Aug 5, 2026 | +8.0% |
| Q1 2026 | Jun 3, 2026 | +0.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| UEG Week 2026 Investor Webcast | Conference | 47 slides | Oct 20, 2026 |
| Investor Presentation (October 2026) | Investor deck | 45 slides | Oct 20, 2026 |
| Investor Presentation (September 2026) | Investor deck | 41 slides | September 2026 |
| Investor Presentation (June 2026) | Investor deck | 40 slides | Jun 23, 2026 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$18 a share Use of proceeds: Advance OD-001 and the broader portfolio, including SLC15A4 inhibitor OD-002 | Jun 17, 2026 |
| Private placement of common stock Closed: US$18 a share | Jun 17, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on May 7, 2026.
- Price
- US$18.00 a share
- Shares offered
- 15,500,000 shares of common stock
- Offering size
- US$279 million
- Underwriters' option
- Up to 2,325,000 more shares
- Listing
- ODTX on the Nasdaq Capital Market
- Underwriters
- J.P. Morgan, TD Cowen, Cantor, Wedbush PacGrow, Oppenheimer & Co. · In the order on the cover
- Shares delivered
- On or about May 11, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 6, 2026 |
| Filed publicly | Apr 17, 2026 |
| Amended once | May 4, 2026 |
| Shares registered with an exchange | May 5, 2026 |
| Declared effective by the SEC | May 7, 2026 |
| Final prospectus, with the price | May 8, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 8, 2026 |
| EFFECT · Notice that a registration is effective | May 7, 2026 |
| S-1MEF · Registration of more shares for the same offering | May 7, 2026 |
| CERT · Exchange's certificate of listing | May 7, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | May 5, 2026 |
| S-1/A · Registration statement, amended | May 4, 2026 |
| S-1 · Registration statement | Apr 17, 2026 |
| DRS/A · Draft registration statement, amended | Apr 3, 2026 |
| DRS/A · Draft registration statement, amended | Mar 16, 2026 |
| DRS · Draft registration statement | Feb 6, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed May 8, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 2.98M | 4.47M | 1.04M | 0 |
| Gross profit | 2.98M | |||
| Research and development | 126.6M | 112.6M | 112.3M | 101.8M |
| Selling, general and administrative | 37.5M | 27.1M | 22.2M | 21.0M |
| Operating income | -161.2M | -135.2M | -133.4M | -122.8M |
| Depreciation and amortization | 4.91M | 5.19M | 4.91M | 2.76M |
| EBITDA | -156.2M | -130.0M | -128.5M | -120.0M |
| Interest expense | 17.0K | 18.0K | 335.0K | 291.0K |
| Income before tax | -149.6M | -128.9M | -125.5M | -124.3M |
| Income tax | -927.0K | |||
| Net income | -148.6M | -129.3M | -125.9M | -124.7M |
| Earnings per share, basic | -5.39 | -2.74 | -2.67 | -2.64 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 41.7M | 59.1M | 52.5M | 241.0M |
| Short-term investments | 139.7M | 70.2M | 134.5M | 0 |
| Current assets | 190.7M | 135.5M | 192.5M | 248.7M |
| Goodwill | 14.3M | 13.3M | 13.6M | 12.9M |
| Total assets | 269.8M | 197.4M | 286.5M | 317.1M |
| Accounts payable | 7.87M | 6.32M | 7.73M | 8.05M |
| Current liabilities | 26.5M | 28.4M | 22.1M | 22.8M |
| Long-term debt | 4.76M | |||
| Total debt | 27.1M | |||
| Total liabilities | 758.1M | 580.0M | 549.2M | 461.8M |
| Shareholders' equity | -488.3M | -382.5M | -262.7M | -144.6M |
| Shares outstanding | 27.6M | 47.2M | 47.2M | 47.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -129.5M | -117.5M | -112.7M | -99.8M |
| Capital spending | -1.23M | -764.0K | -5.06M | -13.0M |
| Free cash flow | -130.7M | -118.2M | -117.8M | -112.9M |
| Cash from investing | -103.9M | |||
| Cash from financing | 215.6M | 27.0M | 92.1M | 182.7M |
| Change in cash | -17.4M | 6.34M | -185.7M | 69.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 8-K · Current report | Jun 23, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Jun 17, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jun 17, 2026 | Results | SEC |
All 72 filings
Cap table
Built by 6ix from Odyssey Therapeutics, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 48,067,877
- Fully diluted
- 48,067,877
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 48,067,877 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 48,067,877 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Timothy P. Walbert Other companies: Latigo Biotherapeutics, Inc. (Chair, Board of Directors · Since at least Aug 6, 2026); Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 24, 2025); Sagimet Biosciences Inc. - Series A (Director · Since at least Apr 1, 2024); Mirum Pharmaceuticals, Inc. (Director · Since at least Apr 5, 2023); Century Therapeutics, Inc. (Director · Since at least Oct 1, 2022); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2022 · Past); Assertio Holdings, Inc. (Director · May 20, 2020 – May 20, 2020 · Past); Exicure, Inc. (Director · Jul 22, 2019 – Jun 2, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Oct 12, 2015 – Feb 13, 2018 · Past); Egalet Corporation (Director · Mar 10, 2014 – May 20, 2020 · Past); Horizon Pharma PLC (Chairman, President and CEO, Director · Jul 28, 2011 – Mar 23, 2019 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Mar 13, 2014 · Past); Idm Pharma Inc (President and CEO, Director · May 25, 2007 – Apr 3, 2008 · Past) | Director · Since at least May 7, 2026 |
| Ian Smith Other companies: Stoke Therapeutics, Inc. (Chief Executive Officer & Director · Since at least Sep 19, 2023); Foghorn Therapeutics Inc. (Director · Since at least Apr 27, 2021); Solid Biosciences Inc. (Chairman of the Board · Since at least Apr 15, 2020); IVERIC bio Inc (Director · Aug 2, 2016 – Aug 2, 2016 · Past); Acorda Therapeutics Inc (Director · Feb 1, 2007 – Jun 27, 2018 · Past); Vertex Pharmaceuticals Incorporated (EVP, COO · Jan 23, 2006 – Jun 29, 2018 · Past) | Director · Since at least May 7, 2026 |
| Jeffrey Leiden Other companies: Vertex Pharmaceuticals Incorporated (Executive Chairman · Since at least Jul 21, 2015); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Quest Diagnostics Incorporated (Director · Jul 1, 2015 – May 29, 2018 · Past) | Director · Since at least May 7, 2026 |
| Carolyn Ng Other companies: Bicara Therapeutics Inc. (Director · Sep 12, 2024 – Sep 12, 2024 · Past); Bicycle Therapeutics PLC (Director · May 22, 2019 – May 28, 2019 · Past) | Director · Since at least May 7, 2026 |
| Jason Haas Other companies: Ligand Pharmaceuticals Incorporated (Director · Since at least Jun 29, 2022); Syros Pharmaceuticals, Inc. (Chief Financial Officer · Oct 12, 2021 – Nov 18, 2024 · Past) | Chief Financial Officer · Since at least May 7, 2026 |
| Ourania Tatsis Other companies: Verve Therapeutics Inc (Director · Since at least Jun 26, 2024); Vertex Pharmaceuticals Incorporated (EVP, Chief Reg. & Quality Off. · Since at least Oct 1, 2019) | Director · Since at least May 7, 2026 |
| Paulina Hill Other companies: Neuronetics, Inc. (Director · Jun 27, 2018 – Jul 2, 2018 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 12, 2018 · Past) | Director · Since at least May 7, 2026 |
| Jolie Siegel Other companies: C4 Therapeutics, Inc. (Chief Legal Officer · Oct 1, 2020 – Feb 13, 2025 · Past) | See Remarks · Since at least May 7, 2026 |
| Shelley Chu Other companies: Hillevax Inc (Director · Since at least Apr 28, 2022) | Director · Since at least May 7, 2026 |
| Valerie Odegard Other companies: ARS Pharmaceuticals, Inc. (President and CSO · Dec 3, 2020 – May 2, 2022 · Past) | Director · Since at least May 7, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Anthony W Opipari | See Remarks · Since at least May 7, 2026 |
| Aranicki Ksenija Pavletic | Director · Since at least May 7, 2026 |
| Collin M Todd | See Remarks · Since at least May 7, 2026 |
| Gary D. Glick | Founder, President & CEO · Since at least May 7, 2026 |
| Nan Li | Director · Since at least May 7, 2026 |
| Natalie Dales | See Remarks · Since at least May 7, 2026 |
Log in to ask 6ix AI your own questions about Odyssey Therapeutics, Inc.